Specialty Drug “Value-Based” Formulary Tiering Needs Transparency – AMA
Executive Summary
The American Medical Association is concerned that "value-based" formulary tiering structures will lack sufficient transparency regarding patients' out-of-pocket costs for specialty pharmaceuticals